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The objective of this report is to describe an urban county hospital human immunodeﬁciency virus (HIV) infection prevention
protocol oﬀering prophylactic combination antiretroviral medications to female victims of sexual assault. A retrospective chart
review was conducted from June, 2007 through June, 2008 of 151 women who were prescribed antiretroviral prophylaxis by
protocol. All women receiving HIV prophylaxis initially screened HIV seronegative. Of the 58 women who reported taking any
HIV prophylaxis, 36 (62%) were HIV screened at 12 and/or 24 weeks and none had HIV seroconverted. Although the initiation
of an HIV post exposure prophylaxis protocol for sexual assault in a county hospital population is feasible, patient follow-up for
counseling and HIV serostatus evaluation is an identiﬁed barrier
1.Introduction
The 2006 United States Census Bureau lists Dallas County,
Texas, as a county of 2,345,815 individuals where approx-
imately 1 of every 200 people is thought to be human
immunodeﬁciency virus (HIV) seropositive [1, 2]. Human
immunodeﬁciency virus prevalence among convicted sexual
assault assailants may be twice the general male population
which emphasizes the higher risk of HIV exposure following
sexual assault [3].
Well-developed perinatal and postnatal HIV prophylaxis
studies and the resultant protocols for reducing mother-
to-child transmission include neonate prophylaxis which is
believed to additionally protect the infant against infection
from maternal HIV exposure during labor and delivery [4].
However, for ethical reasons and due to the inability to
design a conclusive investigation, randomized and placebo
controlled studies of sexual, nonoccupational postexposure
prophylaxis (nPEP) will never be available. Data collected
from an animal simian immunodeﬁciency virus transmis-
sion model in the macaque [5] and studies of health care
workersreceiving occupational postexposure prophylaxis [6]
suggest that nPEP might reduce the risk for HIV infection
after unanticipated sexual exposure. In an observational
study of sexual assault survivors in Brazil, 180 women
treated with combinations of zidovudine, lamivudine, and
indinavir remained HIV seronegative while 4 (2.7%) of
145 untreated women seroconverted [7]. Although no study
provides deﬁnitive evidence for the eﬃcacy of sexual assault
HIV nPEP, cumulative human, animal, and laboratory data
demonstrate that timely antiretroviral therapy might reduce
the risk for acquiring HIV infection.
In 2005, the United States Department of Health and
Human Services Centers for Disease Control (CDC) out-
lined recommendations for the provision of combination
antiretroviral medications to prevent HIV infection after
unanticipated sexual exposure [1]. Based on this recom-
mendation, Parkland Health and Hospital System (PHHS)
developed and implemented an HIV nPEP protocol to pro-
vide female sexual assault victims with standard health care
guidelines for HIV-infection prevention. Our study presents
a retrospective review of this protocol which provides high-
risk sexual assault victims with antiretroviral prophylaxis
medications.2 Obstetrics and Gynecology International
Table 1: Key elements to consider prior to HIV postexposure
prophylaxis.
(i) Probability that the assailant(s) is HIV infected
(ii) Treatment initiated within 24 not to exceed 72 hours after
exposure
(iii) Victim ability to comply with drugs as prescribed
(iv) Risk of HIV transmission by a particular exposure
(v) Condom use during exposure reduces exposure risk
Adapted from the CDC MMWR 2005 [1].
2.MaterialsandMethods
In a collaborative PHHS eﬀort that involved multiple
disciplines including Obstetrics and Gynecology, Infectious
Diseases, Patient Advocacy, and the Central Pharmacy,
a Sexual Assault HIV Postexposure Prophylaxis Proto-
col (HIV nPEP) was designed. Using the CDC 2005
Guidelines for Antiretroviral Postexposure Prophylaxis after
Non-occupational Exposure to HIV [1], the protocol was
written to provide Noninfectious Disease specialists with
clear assistance in victim counseling, in the prescribing
of antiretroviral medications, and in arranging outpatient
surveillance. The protocol also provided the framework
from which cost underwriting for prophylaxis was linked
to monetary assistance from the Texas State Crime Victims’
Compensation Program (CVCP).
Parkland Health and Hospital System is a large county
hospital which provides emergency medical care to women
and to Dallas County sexual assault victims through its
Women’s Intermediate Care Center (ICC). Upon arrival
to PHHS, sexual assault victims aged 13 years and older
are triaged for trauma which, if present, is immediately
managed by the Trauma Emergency Department. Following
traumastabilization,thevictimisthentransferredtotheICC
where specially trained rape counselors from the hospital’s
Victim Intervention Program/Rape Crisis (VIP) address
emotional needs and assist with enrollment in the Texas
CVCP. If the assault occurred within 72 hours and was either
unprotected penis to vagina or rectum penetration, HIV
nPEP labs are drawn. The University of Texas Southwestern
Medical Center at Dallas (UTSW) Department of Obstetrics
and Gynecology faculty provide all female forensic medical
examinations and laboratory interpretations during which
they screen the victim for high-risk HIV transmission
elements. If the victim potentially qualiﬁes for HIV nPEP,
further counseling is provided by trained faculty outlining
the risk of single-episode HIV transmission, the avail-
ability and known side eﬀects of short-term antiretroviral
prophylaxis, the necessary medication compliance required
during the multidrug 28-day dosing regimen, and the
need for further clinical evaluation and management. Once
the victim understands counseling elements and agrees to
receive HIV nPEP, prescriptions for combination antiretro-
virals are provided which are initially ﬁlled without charge
from the PHHS Central Pharmacy pending Texas CVCP
funding.
Table 2: HIV transmission risk from known HIV seropositive
exposure.
(i) Blood transfusion: 9,000 per 10,000 exposures
(ii) Needles sharing injection drug use: 67 per 10,000
exposures
(iii) Receptive anal intercourse: 50 per 10,000 exposures
(iv) Percutaneous needle stick: 30 per 10,000 exposures
(v) Receptive penile-vaginal intercourse: 10 per 10,000
exposures
(vi) Receptive oral intercourse: 1 per 10,000 exposures
Adapted from CDC MMWR 2005 [1].
Because HIV nPEP after sexual assault remains an
unproven clinical intervention, its provision should be
oﬀered on an individualized victim basis, but from standard-
ized guidelines provided by a written protocol. The decision
to proceed with HIV nPEP after a sexual encounter comes
from the consideration of the ﬁve elements listed in Table 1
which trained faculty discuss in detail with the victim. The
probability that the assailant is HIV infected is higher if the
assailant uses illicit drugs, practices homosexual or bisexual
activity, is a commercial sex worker, or if the assault occurs
in a high-prevalence population. Antiretroviral prophylaxis
is less likely to be eﬀective if initiated later than 72 hours
after HIV exposure. Medication compliance requires the
patienttocompletea28-daycourseofmultipleantiretroviral
medications. A single episode risk of HIV transmission
from a known infected source is dependent upon the
exposure route (Table 2). Condom use during exposure
reduces the exposure risk [8] whereas previous consensual,
unprotected intercourse with the contact negates the beneﬁt
of prophylaxis.
Comprehensivepatientcounselingisintegraltoinitiating
any medical treatment that lacks a clearly proven beneﬁt
especially if the treatment has known side eﬀects and
toxicities. Antiretroviral medications selected for use in
the PHHS HIV nPEP protocol include lopinavir/ritonavir
(Kaletra) and emtricitabine/tenofovir (Truvada) or zidovu-
dine/lamivudine (Combivir). Collectively, short-term side
eﬀects and toxicities for these medications may include gas-
trointestinal intolerance, asthenia, elevated transaminases,
hyperglycemia, lipid abnormalities, bone marrow suppres-
sion, headache, insomnia, myopathy, hepatic steatosis, and
renal impairment.
Medications selected for HIV prophylaxis depend upon
thepatient’sage,pregnancystatus,andlaboratorytestvalues.
The HIV nPEP medication proﬁle is detailed in Table 3.
Assault victims qualiﬁed for HIV nPEP receive a baseline
laboratory screen to ascertain the most appropriate HIV
antiretroviral medication and dose to prescribe. Laboratory
testing for the victim’s initial HIV serostatus plus screening
for the sexually transmitted diseases: Hepatitis B, Hepatitis
C, syphilis, gonorrhea, and chlamydia are obtained. Any
abnormal liver function and electrolyte test, creatinine clear-
ance,orcompletebloodcountprompts InfectiousDiseaseor
Pharmacy assistance in selecting the safest HIV medication
and dose.Obstetrics and Gynecology International 3
Table 3: HIV nPEP antiviral medications doses.
(1) If the patient is ≥18 years of age with a negative urine pregnancy test, normal liver function and complete
blood count tests, and a creatinine clearance of ≥50mL/minute:
Emtricitabine/tenofovir: one tablet by mouth every day for twenty-eight days
PLUS
Lopinavir/ritonivir: two tablets by mouth twice daily for twenty-eight days
(2) If the patient is ≥12 and <18 years of age or is pregnant at any age with normal liver function and complete
blood count tests and a creatinine clearance of ≥50mL/minute:
Lamivudine/zidovudine: one tablet by mouth twice daily for twenty-eight days
PLUS
Lopinavir/ritonivir: two tablets by mouth twice daily for twenty-eight days
(3) Patients with Hepatitis B or C may be given emtricitabine/tenofovir and lopinavir/ritonivir as long as their
baseline liver function tests are normal.
(4) Patients with baseline abnormal renal function should not receive emtricitabine/tenofovir. Instead, they
should be started on lopinavir/ritonavir (as above) plus lamivudine/zidovudine with dosing adjustments listed
below.
Dosage adjustments for patients ≥12 years of age with CrCL <50mL/minute
CrCL Renal dosage
30–49mL/minute Lamivudine 150mg tablet QDay zidovudine 300mg
tablet BID
15–29mL/minute Lamivudine oral solution 100mg/10mL QDay
zidovudine 300mg tablet BID
5–14mL/minute Lamivudine oral solution 50mg/5mL QDay
zidovudine 300mg tablet BID
<5mL/minute Lamivudine oral solution 25mg/2.5mL
QDayzidovudine 300mg tablet QDay
Adapted from CDC MMWR 2005 [1].
Continued care for sexual assault victims receiving HIV
nPEP is provided by scheduled followup examinations at
2, 4, 12, and 24 weeks at a select PHHS Women’s Clinic.
During the victim’s initial two-week followup, medication
compliance and side eﬀects are assessed and documented,
ongoing ACA VIP counseling is scheduled as requested
by the patient, and repeat labs, including liver function
and electrolyte tests, creatinine clearance, and complete
blood count, are evaluated. A UTSW Infectious Disease or
HIV Pharmacist phone consult is obtained for abnormal
lab results or for unmanageable medication side eﬀects.
Additional HIV serotesting is obtained at 4, 12, and 24 weeks
postexposure. Seroconversion is reported following state and
federalguidelineswhereuponfurtherpatientcareisarranged
with an Infectious Disease specialist.
To evaluate the eﬃcacy of the PHHS HIV nPEP protocol,
medical charts of sexual assault victims receiving proto-
col driven antiretroviral prophylaxis were retrospectively
reviewed with permission granted from the Institutional
Review Board of the UTSW Medical Center at Dallas.
Patients studied were female sexual assault victims from
PHHS registered between June 18, 2007 and June 19, 2008.
Group comparisons were made using the chi-square
test for categorical data and student’s t-test for continuous
measures.P-valueslessthan0.05wereconsideredstatistically
signiﬁcant. All analyses were performed using SAS version
9.1 (SAS Institute, Cary, N.C.).
3. Results
The PHHS HIV nPEP protocol was initiated on June 18,
2007. In the ﬁrst 12 months, we evaluated 660 sexual
assault patients. One hundred and ﬁfty-one received HIV
nPEP medications. The demographic characteristics of these
women are detailed in Table 4. The age of the women
a c c e p t i n gH I Vn P E Pr a n g e df r o m1 3t o6 1y e a r s .F o u r t e e n
percent of the women resided outside Dallas County.
The majority of women were brought to the hospital by
emergency medical services or the Dallas County Police
Department. Trauma services evaluated and stabilized 15
women (10%) for traumas external to the genital tract.
Baseline laboratory assessment was normal in 129
women (85%). Abnormal laboratory ﬁndings are listed in
Table 5. No woman had a laboratory ﬁnding that aﬀected the
use of standard HIV nPEP medications. Baseline HIV and
Hepatitis B serologic testing were negative in all women. Five
women (3%) were Hepatitis C positive but all had normal
liver function testing. One woman was pregnant and was
started on lamivudine/zidovudine and lopinavir/ritonavir
perprotocol.Two(1%)womenwerediagnosedwithsyphilis,
17(11%)womenwithChlamydia,and7(5%)withgonococ-
cal cervicitis at the time of initial evaluation which reﬂects
infection prevalence in the ICC emergency care population.
There are multiple known drug interactions associated
with antiretroviral medications. Thirty-four women (23%)
were taking at least one medication known to have potential4 Obstetrics and Gynecology International
Table 4: Characteristics of the women receiving HIV nPEP
medications.
Cohort
N = 151
Age (mean years ± SD) 30 ± 11
<18 years of age 43 (28)
Range (years) 13–61
Race
African-American 57 (38)
Caucasian 57 (38)
Hispanic 37 (24)
County of residence
Dallas 130 (86)
Out of county (TX) 18 (12)
Out of state 3 (2)
Mode of transport to the hospital
Emergency medical services 16 (11)
Police 69 (46)
Self 64 (42)
Unknown 2 (1)
Trauma service evaluation 15 (10)
Data presented as n (%) unless otherwise noted.
Table 5: Baseline laboratory evaluation prior to receiving HIV
nPEP medications.
Cohort
N = 151
Liver transaminases ≥2SD 0(0)
Hematocrit <35% 17 (11)
Hematocrit <30% 3 (2)
Thrombocytopenia (150,000 platelets) 0 (0)
Glucose >200mg% 2 (1)
Hypophosphatemia 1 (1)
Creatinine >1.2mg/mL 0 (0)
Hepatitis C seropositive 5 (3)
HIV seropositive 0 (0)
Hepatitis B surface antigen 0 (0)
drug interactions with protocol antiretrovirals, mainly psy-
chiatric and oral contraceptive medications. These women
were counseled regarding the potential drug interactions and
possible measures to prevent complications, for example,
condomusetopreventpregnancyduringtheHIVnPEPtime
period.
Sixty-two women (41%) presented to the hospital system
for followup during the study period, where 58 (94%) of
thesewomenself-reportedtakinganyHIVnPEPmedication.
Thirty-seven women (60%) reported taking a 21-day HIV
nPEP or completing the prescribed course of therapy.
Womenpresentingfortheﬁrstsurveillanceappointmentat2
weeks were signiﬁcantly more likely to complete subsequent
followupvisits(P<. 02).Wedidnoteanincreaseinfollowup
rates from the ﬁrst 3 months of the protocol compared
to the last 3 months (38% and 46%, resp.), probably
reﬂecting increased provider familiarity with the protocol
and an associated improvement in patient counseling and
education. Nineteen women had one followup visit, 12 had
2 visits and 31 women completed 3 or more of the scheduled
visits. Women presenting for any followup were signiﬁcantly
younger where 60% of women <18 years of age had at
least one followup visit (Table 6). There were no signiﬁcant
diﬀerences in race or county of residence with regards to
followup.
No woman seroconverted for Hepatitis B or C nor were
there new cases of syphilis identiﬁed. Although there were
no HIV seroconversions during our study, only 15 women
received an HIV test ≥6 months after receiving HIV nPEP.
Five women (8%) who presented for followup had evi-
denceoflaboratorytoxicityfromtheHIVnPEPmedications.
One woman receiving zidovudine developed neutropenia
with an absolute neutrophil count decreasing from 3260 to
1200cells/mm3. One woman had an increase in serum crea-
tinine from 0.87mg/mL baseline to 1.22mg/mL at 2 weeks,
and 3 women had evidence of worsening liver function
though only one required the HIV nPEP medications to be
stopped. Side eﬀects were common; 67% of women reported
at least one side eﬀect with gastrointestinal complaints being
the majority. One woman had an allergic reaction though we
were unable to determine which of her medications was the
source (pain, antibiotic, or HIV nPEP medications). Nine
women reported using prescription or over-the-counter
medication to treat side eﬀects, but only four stopped HIV
nPEP secondary to symptoms. The majority of women who
received followup tolerated the HIV nPEP medications and
were able to complete the 28-day course.
4. Discussion
DeﬁnitivepublisheddataontheeﬃcacyofHIVnPEPamong
those sexually assaulted is lacking. Thus, the decision to
oﬀer combination antiretroviral medication is based on the
rate of infection incurred through diﬀerent types of sexual
intercourse plus the suspected prevalence of HIV infection
among assailants. Undeniably as important as infection rate
statistics, sexual assault victims often express signiﬁcant
anxiety from the fear of contracting an HIV infection
even though the chances of HIV transmission following a
single sexual contact are very low. Data shows immediately
after HIV infection but before a host develops an immune
response, HIV particles replicate and create more than 10
billion new virions per day [9]. With timely combination
antiretroviral therapy, a 50% reduction in viral load can be
seen by day 3 and, thereafter, a further reduction by more
than 99% [10]. Therefore, the possibility of preventing HIV
transmission by prophylaxis should be considered according
to current CDC guidelines [1].
Determining the individual victims risk for infection is
initially based upon ﬁve key elements (Table 1). However,
many of our sexual assault victims are self-identiﬁed sex
workers, current substance abusers, or claimers of previous
consensual sex with the assailant, all of which amplify theObstetrics and Gynecology International 5
Table 6: Comparison of women who presented for followup to those with no followup.
Any Followup N = 62 No Followup N = 89 P-value
Mean age 22.7 ±9.92 6 .6 ±11.5 .03
<18 years of age 26 (42) 17 (19) <. 002
Race
African American 19 (31) 38 (43) NS
Caucasian 23 (37) 34 (38)
Hispanic 20 (32) 17 (19)
County of residence
Dallas 54 (87) 76 (85) NS
Out of county 8 (13) 10 (11)
O u to fs t a t e 0 3( 3 )
overall life-time risk of HIV infection. Many victims are
unwilling to assure medication compliance or decline the
oﬀer of antiretroviral prophylaxis after counseling, accepting
the low-risk of HIV transmission instead. These various
victims’ reasons as data points for not being oﬀered or for
refusing HIV nPEP were not collected during this retrospec-
tive review but will be explored in a future investigation.
The Texas Association Against Sexual Assault in a 2003
survey of emergency rooms providing care for sexual assault
victims found that 70% of respondents oﬀer and discuss
treatment and testing options for HIV [11]. However,
many health care facilities lack a well-deﬁned protocol
for the treatment and surveillance of these patients. The
implementation of such a protocol in the general population
can be diﬃcult and costly, and data are sparse regarding
issues related to such implementation. Even though this
paper illustrates the feasibility of such a protocol, medication
compliance and postassault surveillance remain unclear but
complicated barriers to successful HIV nPEP. With patient
consent, possible solutions may involve a more supportive
case management approach through frequent telephone or
online communications.
The main strength of the PHHS HIV nPEP protocol
comes from the inclusive management of sexual assault vic-
tims within one coordinated hospital setting. From forensics
evidence collection and VIP rape victim advocacy coun-
seling to the actual provision of prescription medications
with ﬁnancial assistance, our protocol guideline supports
continuity of care. Patient followup is provided at a single,
easily accessible PHHS Women’s Clinic by providers trained
to manage sexual assault patients. Ongoing identiﬁcation of
health care inconsistencies that require improvement is more
eﬃcient within a single health care delivery system.
One of the greatest hurdles in implementing this type
of protocol is cost. The average cost of combination
antiretroviral medication for 28 days of prophylaxis is
approximately $1,000 resulting from public health system
outpatient pricing at PHHS. Therefore, simply oﬀering
costly prophylactic medication is insuﬃcient unless funding
arrangements allow immediate drug access. Through a
collaborative eﬀort involving PHHS’s Central Pharmacy,
Departments of Obstetrics and Gynecology and Internal
Medicine/Infectious Diseases Division, and VIP counseling,
high-riskassaultvictimscanbegivenHIVnPEPmedications
underwritten by the hospital but linked to payment by
the Texas CVCP [12]. To accomplish this, the PHHS VIP
providescomprehensivecounselingforsexualassaultvictims
that includes assistance with the CVCP application. Comple-
tion of the CVCP application prompts the Central Pharmacy
to dispense HIV nPEP medications to the patient at no
initial charge. The total cost of prescribing and underwriting
this medication for our 151 high-risk sexual assault patients
was approximately $160,000, a ﬁgure substantially less than
the $385,000 monetary lifetime cost of care for one HIV
seroconversion[13].CrimeVictims’CompensationProgram
funding opportunities, such as that in Texas, are also
availableinmoststatesandshouldbemadereadilyaccessible
to sexual assault victims.
The main weakness of this retrospective review was our
inability to track patient HIV seroconversion beyond our
surveillance schedule due to the lack of patient consent.
Furthermore,determiningifanHIVseroconversionatalater
date was due to an infection received during a sexual assault
and failure of HIV nPEP or from resumed consensual sexual
behavior would be diﬃcult. Although there were no HIV
seroconversions in our study group, only 15 women received
an HIV test at a 6-month or later screen. Prophylactic
medication full compliance and patient followup counseling
remain ongoing protocol issues most likely related to the
challenges providers have in delivering detailed HIV nPEP
information to the emotionally traumatized sexual assault
patient. Patient followup in general improved during the
last 3 months of the study period probably due to increased
provider familiarity with the protocol resulting in enhanced
patient education. Overall, followup in our system was 41%,
a ﬁgure higher than that previously reported in [14], and
self-reported medication compliance was good with 60% of
women stating that they took 21 days or completed their
HIV PEP regimen at their four-week followup appoint-
ment. Gastrointestinal side eﬀects were frequent but rarely
prevented completion of HIV PEP therapy. There were no
unanticipated adverse events.
Human immunodeﬁciency virus nPEP counseling that
promotes informed patients decision making should be
oﬀered to all eligible high-risk sexual assault patients.
Immediate medication accessibility and funding are equally6 Obstetrics and Gynecology International
important if the timely provision of prophylaxis is to be
achieved. A well-deﬁned protocol with continuity of care
provided by a single health care system encourages standard,
high-quality patient management. Individual hospital sys-
tems can successfully adapt the 2005 CDC recommendations
for antiretroviral prophylaxis after nonconsensual sexual
exposure by giving speciﬁc attention to medication funding
and patient surveillance practices.
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